Calliditas: Novartis’ bid on Chinook is a validation of the market potential also for Calliditas and Tarpeyo - Redeye

Novartis has placed a bid; which is formally a merger and the proposal is approved by the boards of directors on both sides, on the US biotech company Chinook Therapeutics at up to USD 3.5bn in mostly cash (USD 3.2bn). We regard the bid as a partly validating the market potential also for Calliditas and the lead asset Tarpeyo.

Länk till analysen i sin helhet: https://www.redeye.se/research/915544/calliditas-novartis-bid-on-chinook-is-a-validation-of-the-market-potential-also-for-calliditas-and-tarpeyo?utm_source=finwire&utm_medium=RSS